Search

List Grid

241 - 250 of 628 Results

  • Pre-Existing Condition Prevalence Among Women Under Age 65

    Issue Brief

    We analyzed data from the 2018 National Health Interview Survey (NHIS) and 2018 Behavioral Risk Factor Surveillance System (BRFSS) to calculate prevalence rates of declinable health conditions. This data note looks at the share of adults ages 18-64 with declinable pre-existing conditions, with a particular focus on women.

  • Racial and Ethnic Health Inequities and Medicare

    Report

    This chart collection draws on primary and secondary data analyses by KFF and other sources to examine the characteristics, experiences, and outcomes of the Medicare population by race and ethnicity

  • What Do We Know About People with High Out-of-Pocket Spending?

    Feature

    Based on an analysis of claims data, this slideshow examines overall trends, gender and age of high out-of-pocket spenders in large employer health plans, as well as differences in out-of-pocket health expenditures across diseases.

  • This Week in Coronavirus: January 22 to January 28

    Policy Watch

    During the 53rd week since the first coronavirus case appeared in the United States, the world surpassed 100 million COVID-19 cases, with the United States accounting for a quarter of them. The U.S. also accounts for one-fifth (433,200) of the world’s nearly 2.2 million reported deaths.

  • Analysis: COVID-19 Ranks as a Top 3 Leading Cause of Death in the U.S., Higher than in Almost All Other Peer Countries

    News Release

    A new KFF analysis examines leading causes of death and mortality rates in the United States and comparable countries. The U.S. has a higher COVID-19 mortality rate than many of its peer countries, with COVID-19 ranking as the nation’s third-leading cause of death in 2020, behind only heart disease and cancer. Among similarly large and wealthy countries, only in Belgium does COVID-19 also rank as the third highest cause of death. COVID-19 ranks fourth in…

  • Explaining the Prescription Drug Provisions in the Build Back Better Act

    Issue Brief

    The Build Back Better Act includes several provisions that would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government and private payers. This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation.